Anlotinib Combined with Penpulimab As First-Line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer: Preliminary Results from ALTER-GO-020, a Single-Arm, Open-Label, Multi-Cohort, Multi-Center Phase II Clinical Study.
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined